One-Year Outcomes for Patients Undergoing Transcatheter Aortic Valve Replacement: The Gulf TAVR Registry.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
08 2022
Historique:
received: 05 10 2021
revised: 22 12 2021
accepted: 22 12 2021
pubmed: 17 1 2022
medline: 20 7 2022
entrez: 16 1 2022
Statut: ppublish

Résumé

The use of transcatheter aortic valve replacement (TAVR) is steadily increasing with TAVR procedures offered to patients across the entire spectrum of surgical risks. The Gulf TAVR registry captures the demographics of patients undergoing TAVR in the Gulf region, comorbidities that drive outcomes, procedural success, complications, and one-year outcomes of death or rehospitalization. This is a retrospective cohort study for adult patients aged at least 18 years undergoing TAVR at eight centers in the Gulf region. The primary outcome was a composite of death or re-hospitalization at one-year. Secondary outcomes included the individual components of the composite, stroke, and myocardial infarction (MI). We used multivariable Cox regression to determine factors associated with the composite endpoint. A total of 795 patients (56% male) were included in the final analysis with a mean age of 74.6 (standard deviation (SD) 8.9) years, Society of Thoracic Surgeons Score (STS) Score 4.9 (4.2), ejection fraction of 53% (12.7%). Transfemoral approach was employed in over 95% (762/795). The primary outcomes rate was 12.8% (95% confidence interval [CI]: 10.6-15.4); secondary endpoints were death 5.4% (95% CI 4.0-7.2); stroke 0.8% (95% CI 0.3, 1.7), MI 0.8% (95% CI 0.4-1.9), rehospitalization: 9.3% (95% CI 7.5-11.5) of whom 71.6% were related to cardiovascular causes. 77% of the cardiovascular admissions were attributable to heart failure or the need for pacemaker implantation. Stage IV or V chronic kidney disease was significantly associated with the primary composite endpoint (Hazard Ratio: 2.49, [95% CI: 1.31, 4.73], p = 0.005). Although not significant, paravalvular leak and severe left ventricular dysfunction showed a 2-fold and 3-fold increased risk for the composite endpoint, respectively. The Gulf TAVR registry is the first of its kind in the region. It profiles an elderly population with a high procedural success rate and a low rate of complications. One-year outcomes were primarily driven by repeat hospitalization for heart failure and pacemaker implantation indicating a need to optimize heart failure management and improve algorithms for the detection of conduction abnormalities.

Sections du résumé

BACKGROUND
The use of transcatheter aortic valve replacement (TAVR) is steadily increasing with TAVR procedures offered to patients across the entire spectrum of surgical risks. The Gulf TAVR registry captures the demographics of patients undergoing TAVR in the Gulf region, comorbidities that drive outcomes, procedural success, complications, and one-year outcomes of death or rehospitalization.
METHODS
This is a retrospective cohort study for adult patients aged at least 18 years undergoing TAVR at eight centers in the Gulf region. The primary outcome was a composite of death or re-hospitalization at one-year. Secondary outcomes included the individual components of the composite, stroke, and myocardial infarction (MI). We used multivariable Cox regression to determine factors associated with the composite endpoint.
RESULTS
A total of 795 patients (56% male) were included in the final analysis with a mean age of 74.6 (standard deviation (SD) 8.9) years, Society of Thoracic Surgeons Score (STS) Score 4.9 (4.2), ejection fraction of 53% (12.7%). Transfemoral approach was employed in over 95% (762/795). The primary outcomes rate was 12.8% (95% confidence interval [CI]: 10.6-15.4); secondary endpoints were death 5.4% (95% CI 4.0-7.2); stroke 0.8% (95% CI 0.3, 1.7), MI 0.8% (95% CI 0.4-1.9), rehospitalization: 9.3% (95% CI 7.5-11.5) of whom 71.6% were related to cardiovascular causes. 77% of the cardiovascular admissions were attributable to heart failure or the need for pacemaker implantation. Stage IV or V chronic kidney disease was significantly associated with the primary composite endpoint (Hazard Ratio: 2.49, [95% CI: 1.31, 4.73], p = 0.005). Although not significant, paravalvular leak and severe left ventricular dysfunction showed a 2-fold and 3-fold increased risk for the composite endpoint, respectively.
CONCLUSIONS
The Gulf TAVR registry is the first of its kind in the region. It profiles an elderly population with a high procedural success rate and a low rate of complications. One-year outcomes were primarily driven by repeat hospitalization for heart failure and pacemaker implantation indicating a need to optimize heart failure management and improve algorithms for the detection of conduction abnormalities.

Identifiants

pubmed: 35033460
pii: S1553-8389(21)00825-3
doi: 10.1016/j.carrev.2021.12.024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-26

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None of the authors has any conflicts of interest or relevant financial disclosures.

Auteurs

Mirvat Alasnag (M)

Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.

Khaled AlMerri (K)

Chest Disease Hospital, Al Shuwaikh, Kuwait city, Kuwait.

Abdulrahman Almoghairi (A)

Prince Sultan Cardiac Center, Riyadh, Saudi Arabia.

Abdullah Alenezi (A)

Chest Disease Hospital, Al Shuwaikh, Kuwait city, Kuwait.

Fawaz Bardooli (F)

Mohammed bin Khalifa Cardiac Centre, Riffa, Bahrain.

Shereen Al-Sheikh (S)

Mohammed bin Khalifa Cardiac Centre, Riffa, Bahrain.

Nouf Alanazi (N)

King Saud University, Riyadh, Saudi Arabia.

Waleed AlHarbi (W)

King Saud University, Riyadh, Saudi Arabia.

Hatim Al Lawati (H)

Sultan Qaboos University Hospital, Muscat, Oman.

Khalid Al Faraidy (K)

King Fahd Military Medical Complex, Dhahran, Saudi Arabia.

Mohammed AlShehri (M)

Prince Khaled Bin Sultan Cardiac Center, Khamis Mushait, Saudi Arabia.

Michael Thabane (M)

Department of Health research methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada; St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada.

Lehana Thabane (L)

Department of Health research methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada; St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada.

Khaled Al-Shaibi (K)

Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia. Electronic address: kfalshaibi@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH